Journal of inflammation research
Cure8 research brief
Why This Matters
Comparative real-world data may help patients and clinicians weigh expected benefits and risks of risankizumab versus ustekinumab in Crohn’s disease, including effects on steroid-free remission and fistula healing.
Who Should Pay Attention
Adults with Crohn's disease, clinicians managing IBD, researchers in biologic therapies, and patients considering or on biologic treatment
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study reviewed consecutive adults starting risankizumab or ustekinumab from 2020–2025 at a single center. Ustekinumab patients had higher 24-week steroid-free clinical remission overall (82.4% vs 46.7%), a difference driven mainly by biologic‑naïve patients.
Risankizumab-treated patients had higher rates of fistula closure (75% vs 29.4%) and fewer reported adverse events in this cohort. The authors note important limitations: retrospective design, baseline imbalances (risankizumab patients appeared more refractory), and possible confounding, so results are hypothesis-generating rather than definitive.
Keep In Mind
Results come from a retrospective single-center cohort with baseline imbalances and potential confounding; findings are informative but not definitive. The source-level content depth is an abstract summary of a journal article.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of inflammation research
AuthorsMeng MJ, Lin SH, Chen CM +5 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedAug 17, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial.
For people with moderate–severe Crohn’s disease who failed anti‑TNF drugs, this trial suggests risankizumab may achieve higher corticosteroid‑free clinical and endoscopic remission than ustekinumab, which could mean...
Real-World Data Show Efficacy of Risankizumab in Refractory Crohn's
This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...
Differentiating IL-23 Inhibitors in Crohn's Disease | Drugs
IL‑23 inhibitors are an important and growing class of drugs for Crohn’s disease. Comparing them helps patients and clinicians understand differences in trial results, approvals, and possible treatment choices.